ESGO-ESHRE-ESGE Guidelines on fertility sparing treatment of patients with cervical cancer, ovarian cancer and borderline ovarian tumours

The European Society of Gynaecological Oncology (ESGO), the European Society of Human reproduction and Embryology (ESHRE) and the European Society for Gynaecological Endoscopy (ESGE) jointly developed clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing strategies and follow-up of patients with cervical cancers, ovarian cancers, and borderline ovarian tumours. The developmental involved an international multidisciplinary development group consisting of 25 experts in gynaecological oncology, oncofertility, reproductive surgery, endoscopy, imaging, conservative surgery, medical oncology, and histopathology.

The article was published in August 2024 in the Lancet Oncology journal:

ESGO-ESHRE-ESGE Guidelines on fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer and borderline ovarian tumours

Working group

The European Society of Gynaecological Oncology (ESGO), the European Society of Human reproduction and Embryology (ESHRE) and the European Society for Gynaecological Endoscopy (ESGE) would like to express their sincere gratitude to the international experts panel, who devoted their time and effort to the ESGO-ESHRE-ESGE Guidelines on fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer and borderline ovarian tumours.

Name	Country	Institution
Philippe Morice	France	Department of Gynecological Surgery, Gustave Roussy Cancer Campus, Villejuif, France Université Paris Saclay, Paris, France
Giovanni Scambia	Italy	Department of Women, Children, and Public Health Sciences
Michael Grynberg	France	Université Paris Saclay, Paris, France Department of Reproductive Medicine and Fertility Preservation, Hopital Antoine Béclère, Clamart, France Department of Reproductive Medicine and Fertility Preservation, Hopital Jean Verdier, Bondy, France
Francois Planchamp	France	Institute Bergonié, Bordeaux, France
Sébastien Gouy	France	Department of Gynecological Surgery, Gustave Roussy Cancer Campus, Villejuif, France Université Paris Saclay, Paris, France
Francesco Fanfani	Italy	Department of Women, Children, and Public Health Sciences
Antonia Testa	Italy	Department of Women, Children, and Public Health Sciences
Denis Querleu	Italy	Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy; Gynecologic Service, Department of Surgery, Division of Gynecologic Oncology
Nadeem Abu-Rustum	Unites States	Memorial Sloan Kettering Cancer Center, New York, NY, USA
Maribel Acien	Spain	Institute of Women’s Health, University College London, London, UK Grant Next Generation Department of Gynecology, Miguel Hernandez University, Alicante, Spain
Alessandro Arena	Italy	Division of Gynaecology and Human Reproduction Physiopathology, IRCCS, Azienda Ospedaliero-Univeristaria di Bologna, Bologna, Italy Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
Sara Brucker	Germany	Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany Department of Women’s Health, University Hospital Tübingen, Tübingen, Germany
Ying Cheong	United Kingdom	Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK
Pierre Collinet	France	Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK
Francesca Filippi	Italy	Infertility Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Ane Gerda Zahl Eriksson	Norway	Department of Gynecologic Oncology, Division of Cancer Medicine, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
Philipp Harter	Germany	Department of Gynaecology and Gynaecologic Oncology, Kliniken Essen Mitte, Essen, Germany
Xavier Matias-Guiu	Spain	Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain
George Pados	Greece	Department of Obstetrics and Gynaecology, Papageorgiou General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Dimitrios Tsolakidis	Greece	Department of Obstetrics and Gynaecology, Papageorgiou General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Maja Pakiz	Slovenia	Department for Gynaecologic and Breast Oncology, University Medical Center Maribor, Maribor, Slovenia
Alexandros Rodolakis	Greece	Unit of Gynaecologic Oncology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece
Christine Rousset-Jablonski	France	Department of Surgery, Centre Léon Bérard, Lyon, France
Artem Stepanyan	Armenia	Gynecologic Oncology Service, Nairi Medical Center, Yerevan, Armenia
Kirsten LouiseTryde Macklon	Denmark	Fertility Clinic, Department of Gynecology, Fertility and Obstetrics Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Michel De Vos	Belgium	Centre for Reproductive Medicine, University Hospital Brussels, Brussels, Belgium Follicle Biology Laboratory, Vrije Universiteit Brussel, Brussels, Belgium

 

External reviewers

120 reviewers - 40 countries

ESGO would also like to thank external reviewers who have taken the time to provide their feedback on the document elaborated in the framework of the ESGO-ESHRE-ESGE Guidelines on fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer and borderline ovarian tumours:

List of external reviewers